23:04 , May 8, 2019 |  BC Extra  |  Preclinical News

May 8 Preclinical Quick Takes: Moderna, WntRx, schizophrenia, heart attack

Moderna debuts candidate for rare glycogen storage disease  Moderna Inc. (NASDAQ:MRNA) revealed a new preclinical mRNA candidate to treat glycogen storage disease type Ia -- mRNA-3745, which encodes G6PC. The company presented data at the...
02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
20:28 , Oct 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture studies identified an oligomer macrocycle-based inhibitor of the β-catenin-TCF4 interaction that could help treat prostate cancer. Chemical synthesis of oligomer macrocycles designed to inhibit the interaction between TCF4 and β-catenin,...
17:39 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Cell culture and mouse studies identified a Wnt/β-catenin pathway inhibitor and p53 activator that could help treat colorectal cancer. Screening of a small molecule library in a human cell-based assay of Wnt/β-catenin-dependent...
19:37 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Mouse studies suggest combined inhibition of EGFR and β-catenin could help treat EGFR-mutant NSCLC. In two xenograft mouse models of EGFR-mutant NSCLC, the EGFR inhibitor Tarceva erlotinib and a...
18:59 , Aug 15, 2018 |  BC Extra  |  Preclinical News

Gene transfer regenerates rod cells, restores light sensitivity in blind mice

Researchers at the Icahn School of Medicine at Mount Sinai developed a gene transfer process to generate rod photoreceptors that restored light sensitivity in mice with congenital blindness. In a paper published Wednesday in Nature...
18:22 , May 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Patient sample, cell culture and mouse studies suggest inhibiting β-catenin in combination with Xtandi enzalutamide could help treat prostate cancer. In tumor samples from prostate cancer patients, levels of β-catenin were higher...
19:13 , May 18, 2018 |  BC Week In Review  |  Financial News

Stapled peptide company FOG raises $66M series B

FOG Pharmaceuticals Inc. (Cambridge, Mass.) raised $66 million in a series B round led by 6 Dimensions Capital. New investors GV, Blue Pool Capital, Horizons Ventures, Nan Fung Group and Leerink Partners also participated, as...
12:01 , May 16, 2018 |  BC Extra  |  Financial News

Stapled peptide company FOG raises $66M series B

FOG Pharmaceuticals Inc. (Cambridge, Mass.) raised $66 million in a series B round led by 6 Dimensions Capital. New investors GV, Blue Pool Capital, Horizons Ventures, Nan Fung Group and Leerink Partners also participated, as...